Confirmation of Powassan Virus (POWV) can be determined through Coppe Laboratories’ IgG/IgM Powassan Virus Testing. It is the only commercially available Powassan Virus test on the market today. While the CDC and a few state laboratories provide Powassan IgM testing, Coppe Laboratories’ IgG/IgM testing is available to healthcare providers looking for answers when suspected past tick involvement causes neurologic disability and sometimes permanent cognitive impairment.
In December of 2020, Coppe Laboratories was granted a license by the New York State Department of Health (NYSDOH) to offer Powassan Virus (POWV) and West Nile Virus (WNV) antibody testing as well as Immunohistochemistry (IHC) for HHV-6.
For the last four years, Coppe Laboratories’ mission has been to ensure all patients have access to clinically-relevant diagnostic testing that allows patients and physicians to make the most informed treatment decisions. Groundbreaking research and development is what has made Coppe Laboratories a leading provider of diagnostic tests with diverse applications.
A new research study conducted by Coppe Laboratories indicates ticks are carrying both Lyme and Powassan simultaneously.
Concern over Powassan virus is rapidly expanding across many U.S states, and for good reason: Powassan virus is carried by the same ticks that transmit the bacteria that cause Lyme disease.